Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-09-30

Study Completion Date

2015-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the activity of the FGFR inhibitor AZD4547 in patients with FGFR1 or FGFR2 amplified breast, squamous lung and stomach cancer whose cancers have progressed following previous chemotherapy

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547

NCT05086666

Urothelial Carcinoma

UNKNOWN PHASE1/PHASE2

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

NCT02965378

FGFR1 Gene Amplification FGFR1 Gene Mutation FGFR2 Gene Amplification +5 more

COMPLETED PHASE2/PHASE3

Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer

NCT02228369

EGFR Mutation Positive Advanced Non Small Cell Lung Cancer

COMPLETED PHASE1

Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer

NCT02163733

Advanced Non Small Cell Lung Cancer Advanced (Inoperable) Non Small Cell Lung Cancer

COMPLETED PHASE1

Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC

NCT02197234

Non Small Cell Lung Cancer

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary endpoint

\- To assess anti-tumour activity as change in tumour size at 8 weeks and the correlation with change in tumour ERK1/2 phosphorylation at day 10-14.

Secondary endpoints

* Objective response rate to AZD4547 in all patients and in each tumour group
* Safety and tolerability of AZD4547 in all patients
* Disease control rate at 8 weeks
* Progression free survival in all patients and in each tumour group

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastric Cancer Oesophageal Cancer Breast Cancer Squamous Cell Carcinoma of the Lung

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single Treatment Arm

16-24 patients per tumour group will be treated with AZD4547 administered 80mg twice daily, 2 weeks on, 1 week off in 21 days cycles.

Group Type EXPERIMENTAL

AZD 4547

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AZD 4547

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female or male aged 25 years or older.
* Mandatory provision of archival or fresh tumour biopsy for confirmation of FGFR gene amplification.
* World Health Organisation performance status 0-2, minimum life expectancy of 12 weeks from proposed first dose date
* Patient ability to comply with the collection of tumor biopsies which is mandatory at baseline and on days 10-14
* Calcium and phosphate within normal limits.
* At least one lesion, not previously irradiated, that can be accurately measured at baseline as \>=10 mm in the longest diameter - except lymph nodes which must have short axis \>=15 mm.
* Local disease confined to the stomach or oesophagus is not considered measurable (patients with locally advanced gastro-oesophageal adenocarcinoma must have at least one measurable nodal lesion \>=15mm in the short axis).

Advanced gastro-oesophageal adenocarcinoma

* Histologically proven metastatic or locally advanced inoperable adenocarcinoma of the stomach, lower oesophagus or oesophago-gastric junction.
* Documented progression after 1 or 2 prior courses of chemotherapy for advanced disease,
* FGFR2 amplification

Advanced breast carcinoma

* Histologically confirmed metastatic or locally advanced breast cancer, negative for HER2 as determined by local laboratory.
* Patients with locally advanced disease must have recurrent, or progressive, disease that is not suitable for treatment with curative intent
* Patients with ER positive disease must have been treated with at least one line of hormonal therapy for recurrent/progressive disease or have been on hormonal therapy at the time of recurrence/progression
* Documented progression after at least one and no more than three prior courses of chemotherapy for advanced disease.
* FGFR1 amplification

Advanced squamous cell lung cancer

* Histologically confirmed metastatic or locally advanced squamous cell carcinoma of lung
* Documented progression after 1 or 2 prior courses of chemotherapy for advanced disease
* FGFR1 amplification

Exclusion Criteria

* Treatment potent inhibitors or inducers of CYP3A4, 2C8 or 2D6 or substrates of CYP3A4 within specified durations prior to the first dose of study treatment
* Major surgery (excluding placement of vascular access) within 4 weeks before the first dose of study treatment
* Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 2 weeks before the first dose of study treatment
* Prior exposure to AZD4547 or any other drug with FGFR inhibition as its primary mode of action
* Untreated brain metastases
* Inadequate bone marrow reserve or organ function
* Corrected total calcium \> ULN
* Total phosphate \> ULN
* Mean resting corrected QT interval \> 470 msec obtained from 3 consecutive electrocardiograms (ECGs)
* Any of the following ophthalmological criteria: 1)Current evidence or previous history of retinal pigmented epithelium detachment (RPED). 2)Previous laser treatment or intra-ocular injection for treatment of macular degeneration. 3) Current evidence or previous history of dry or wet age-related macular degeneration. 4) Current evidence or previous history of retinal vein occlusion (RVO). 5) Current evidence or previous history of retinal degenerative diseases (e.g. hereditary). 6) Current evidence or previous history of any other clinically relevant chorioretinal defect

Minimum Eligible Age

25 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No